Premium
Utility of rotational atherectomy and outcomes over an eight‐year period
Author(s) -
Couper Lachlan T.,
Loane Philippa,
Andrianopoulos Nick,
Brennan Angela,
Nanayakkara Shane,
Nerlekar Nitesh,
Scott Peter,
Walton Anthony S.,
Clark David J.,
Duffy Stephen J.,
Ajani Andrew E,
Reid Chris,
Shaw James A.
Publication year - 2015
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.26077
Subject(s) - medicine , mace , conventional pci , percutaneous coronary intervention , incidence (geometry) , surgery , population , angioplasty , cardiology , myocardial infarction , physics , environmental health , optics
Objectives To evaluate outcomes of patients undergoing rotational atherectomy (RA) in a multicenter percutaneous coronary intervention (PCI) registry. Background RA remains an important technique for plaque modification in PCI, particularly with complex calcification. Methods The study population consisted of consecutive patients undergoing PCI in nine major Australian hospitals, who were treated over an 8‐year period (June 2004 to June 2012). Results Of 16,577 PCI's, 1.0% of patients n = 167 (214 lesions) underwent RA. Patients undergoing RA were more likely to be older (71.0 ± 9.7 vs. 64.4 ±11.9 years, P < 0.01), with greater incidence of diabetes (37.7% vs. 23.8%, P < 0.01) and renal impairment. There was no significant difference in procedural success (94.6% vs. 95.5%, P = 0.57), dissection (6.1% vs. 4.8%, P = 0.39), transient no reflow (4.4% vs. 2.8%, P = 0.23), or persistent no reflow (0% RA vs. 0.7% non‐RA, P = 0.23). Those undergoing RA had a low but increased risk of death at 12 months (6.6 vs. 3.6%, P = 0.04). There was no significant difference in 12 month major adverse cardiovascular outcomes (MACE) between groups following adjustment for univariate predictors (OR 1.00, 95%CI; 0.93–1.08). Additionally, there was no significant difference in 30‐day MACE (6.0% vs. 5.1%, P = 0.62) or 30‐day mortality (2.4% vs. 1.8%, P = 0.54) between groups. Conclusions In this large multicenter registry, RA continues to be used to treat complex lesions with low procedural complications and MACE rates. It is essential for interventional cardiologists to maintain skills in RA to enable effective percutaneous treatment of certain complex lesions. © 2015 Wiley Periodicals, Inc.